ArticleInternational journal of clinical oncology2022

Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series.

Tomohiro Iwasawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.